HK1080856A1 - Compounds having selective inhibiting effect at gsk3 - Google Patents
Compounds having selective inhibiting effect at gsk3Info
- Publication number
- HK1080856A1 HK1080856A1 HK06100896.9A HK06100896A HK1080856A1 HK 1080856 A1 HK1080856 A1 HK 1080856A1 HK 06100896 A HK06100896 A HK 06100896A HK 1080856 A1 HK1080856 A1 HK 1080856A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- alkylnr
- gsk3
- alkylc
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203754A SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | New compounds |
PCT/SE2003/001955 WO2004055005A1 (en) | 2002-12-17 | 2003-12-15 | Novel compounds having selective inhibiting effect at gsk3 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1080856A1 true HK1080856A1 (en) | 2006-05-04 |
Family
ID=20289907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06100896.9A HK1080856A1 (en) | 2002-12-17 | 2006-01-19 | Compounds having selective inhibiting effect at gsk3 |
Country Status (19)
Country | Link |
---|---|
US (2) | US7585853B2 (xx) |
EP (2) | EP2161265A3 (xx) |
JP (1) | JP4674088B2 (xx) |
KR (1) | KR101110457B1 (xx) |
CN (1) | CN100351250C (xx) |
AT (1) | ATE454382T1 (xx) |
AU (1) | AU2003287135B2 (xx) |
BR (1) | BR0317294A (xx) |
CA (1) | CA2508042C (xx) |
DE (1) | DE60330910D1 (xx) |
ES (1) | ES2337682T3 (xx) |
HK (1) | HK1080856A1 (xx) |
IL (1) | IL169016A (xx) |
MX (1) | MXPA05006243A (xx) |
NO (1) | NO331495B1 (xx) |
NZ (1) | NZ540449A (xx) |
SE (1) | SE0203754D0 (xx) |
WO (1) | WO2004055005A1 (xx) |
ZA (1) | ZA200504617B (xx) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
PL1786785T3 (pl) * | 2004-08-26 | 2010-08-31 | Pfizer | Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe |
PT1784396E (pt) * | 2004-08-26 | 2011-01-27 | Pfizer | Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases |
EP2157090A4 (en) * | 2007-06-21 | 2011-09-07 | Taisho Pharmaceutical Co Ltd | PYRAZINAMIDVERBINDUNG |
UA103319C2 (xx) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Сполуки бензенсульфонамідтіазолу та -оксазолу$соединения бензенсульфонамидтиазола и -оксазола |
EP2138485A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
KR101712576B1 (ko) | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 화합물 |
ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
AR078984A1 (es) * | 2009-11-13 | 2011-12-14 | Astrazeneca Ab | Pirazina sustituida con oxazolo (4,5-c) piridina |
MX2012008328A (es) | 2010-01-19 | 2012-08-08 | Astrazeneca Ab | Derivados de pirazina. |
JP5856151B2 (ja) | 2010-05-12 | 2016-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼ阻害剤として有用な2−アミノピリジン誘導体 |
JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用なピラジン |
JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2011143426A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2011163527A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物 |
RS58015B1 (sr) | 2011-05-23 | 2019-02-28 | Merck Patent Gmbh | Piridin- i pirazin derivati |
SG194107A1 (en) | 2011-05-23 | 2013-11-29 | Merck Patent Gmbh | Thiazole derivatives |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
DE102011112978A1 (de) | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2850564A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CA2850566C (en) | 2011-09-30 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
DE102011119127A1 (de) | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
HUE032203T2 (en) | 2012-02-09 | 2017-08-28 | Merck Patent Gmbh | Furo- [3,2-b] pyridine derivatives as TBK1 and IKK inhibitors |
PL2833973T3 (pl) | 2012-04-05 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone |
US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
PT2941432T (pt) | 2012-12-07 | 2018-06-01 | Vertex Pharma | 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oxetan-3- il)piperazina-1-carbonil)piperidin-1-il)piridin-3- il)pirazolo[1,5alfa]pirimidina-3-carboxamida como inibidor da quinase atr |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
PT3077397T (pt) | 2013-12-06 | 2020-01-22 | Vertex Pharma | Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo |
WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
MX2016016115A (es) | 2014-06-17 | 2017-03-08 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2015350315B2 (en) * | 2014-11-18 | 2020-06-25 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA26473A1 (fr) | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
DK1255740T3 (da) * | 2000-02-16 | 2006-02-06 | Neurogen Corp | Substituerede arylpyraziner |
NZ521207A (en) * | 2000-03-07 | 2005-04-29 | Aventis Pharma Gmbh | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
NZ528450A (en) * | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
-
2002
- 2002-12-17 SE SE0203754A patent/SE0203754D0/xx unknown
-
2003
- 2003-12-15 AT AT03781204T patent/ATE454382T1/de not_active IP Right Cessation
- 2003-12-15 US US10/539,543 patent/US7585853B2/en not_active Expired - Fee Related
- 2003-12-15 EP EP09180635A patent/EP2161265A3/en not_active Withdrawn
- 2003-12-15 BR BR0317294-5A patent/BR0317294A/pt not_active IP Right Cessation
- 2003-12-15 AU AU2003287135A patent/AU2003287135B2/en not_active Ceased
- 2003-12-15 WO PCT/SE2003/001955 patent/WO2004055005A1/en active Application Filing
- 2003-12-15 MX MXPA05006243A patent/MXPA05006243A/es active IP Right Grant
- 2003-12-15 DE DE60330910T patent/DE60330910D1/de not_active Expired - Lifetime
- 2003-12-15 CN CNB2003801066631A patent/CN100351250C/zh not_active Expired - Fee Related
- 2003-12-15 KR KR1020057011137A patent/KR101110457B1/ko not_active IP Right Cessation
- 2003-12-15 JP JP2004560223A patent/JP4674088B2/ja not_active Expired - Fee Related
- 2003-12-15 ES ES03781204T patent/ES2337682T3/es not_active Expired - Lifetime
- 2003-12-15 EP EP03781204A patent/EP1575938B1/en not_active Expired - Lifetime
- 2003-12-15 NZ NZ540449A patent/NZ540449A/en not_active IP Right Cessation
- 2003-12-15 CA CA2508042A patent/CA2508042C/en not_active Expired - Fee Related
-
2005
- 2005-06-06 IL IL169016A patent/IL169016A/en not_active IP Right Cessation
- 2005-07-15 NO NO20053460A patent/NO331495B1/no not_active IP Right Cessation
-
2006
- 2006-01-16 ZA ZA200504617A patent/ZA200504617B/en unknown
- 2006-01-19 HK HK06100896.9A patent/HK1080856A1/xx not_active IP Right Cessation
-
2009
- 2009-08-21 US US12/545,213 patent/US20100075989A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4674088B2 (ja) | 2011-04-20 |
EP2161265A2 (en) | 2010-03-10 |
NO20053460L (no) | 2005-08-12 |
ES2337682T3 (es) | 2010-04-28 |
BR0317294A (pt) | 2005-11-08 |
CN1729185A (zh) | 2006-02-01 |
EP2161265A3 (en) | 2010-06-02 |
AU2003287135B2 (en) | 2007-01-25 |
EP1575938B1 (en) | 2010-01-06 |
ATE454382T1 (de) | 2010-01-15 |
EP1575938A1 (en) | 2005-09-21 |
JP2006513180A (ja) | 2006-04-20 |
WO2004055005A1 (en) | 2004-07-01 |
CA2508042C (en) | 2012-01-10 |
KR20050084363A (ko) | 2005-08-26 |
KR101110457B1 (ko) | 2012-02-17 |
US20100075989A1 (en) | 2010-03-25 |
WO2004055005A8 (en) | 2005-06-30 |
US7585853B2 (en) | 2009-09-08 |
DE60330910D1 (de) | 2010-02-25 |
NO331495B1 (no) | 2012-01-16 |
SE0203754D0 (sv) | 2002-12-17 |
CA2508042A1 (en) | 2004-07-01 |
AU2003287135A1 (en) | 2004-07-09 |
ZA200504617B (en) | 2006-03-29 |
CN100351250C (zh) | 2007-11-28 |
MXPA05006243A (es) | 2005-08-19 |
US20060116362A1 (en) | 2006-06-01 |
IL169016A (en) | 2013-08-29 |
NZ540449A (en) | 2008-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1080856A1 (en) | Compounds having selective inhibiting effect at gsk3 | |
NZ511903A (en) | Use of alpha-keto enamine derivatives as ingredients | |
MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
EP1248612A4 (en) | NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS | |
MXPA03007249A (es) | Compuestos triazolo como inhibidores de mmp. | |
PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
WO2004016578A3 (en) | Arylethanolamine beta2-adrenoreceptor agonist compounds | |
BG108420A (en) | New indole derivatives with 5-ht6 receptor affinity | |
NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
NO20015172L (no) | 1-metyl-erytromycin-derivater | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
SE0100569D0 (sv) | New compounds | |
GEP20053505B (en) | Diphenyl Ether Compounds Useful in Therapy | |
AU8799201A (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
SE0201194D0 (sv) | New compounds | |
SE0102055D0 (sv) | New Compounds | |
SE0102440D0 (sv) | New compound | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
MXPA04005076A (es) | Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico. | |
MY140653A (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
TW200505905A (en) | New compounds | |
MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151215 |